Halozyme Therapeutics (HALO) Raw Materials (2011 - 2026)

Halozyme Therapeutics (HALO) has 16 years of Raw Materials data on file, last reported at $21.9 million in Q1 2026.

• Raw Materials for Q1 2026 came in at $21.9 million, up 18.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.9 million (up 18.9% YoY), and the FY2025 annual result was $21.9 million, down 8.94% from the prior year.
• Raw Materials steadied at $21.9 million in Q1 2026 per HALO's latest filing, from $21.9 million in the prior quarter.
• Over five years, Raw Materials peaked at $30.6 million in Q3 2024 and troughed at $10.2 million in Q2 2022.
• A 5-year average of $20.8 million and a median of $21.9 million in 2026 frame the typical range for Raw Materials.
• The sharpest annual moves came in 2023 and 2025: Raw Materials surged 137.5% in 2023, then sank 37.99% in 2025.
• A 5-year view of Raw Materials shows it stood at $13.8 million in 2022, then jumped by 71.45% to $23.6 million in 2023, then increased by 1.56% to $24.0 million in 2024, then decreased by 8.94% to $21.9 million in 2025, then grew by 0.15% to $21.9 million in 2026.
• Business Quant data shows HALO's Raw Materials at $21.9 million in Q1 2026, $21.9 million in Q4 2025, and $19.0 million in Q3 2025.